1
|
S Ramos K, Nassiri S, Wijdeveld LFJ, van der Palen RL, Kuipers MF, Hills MT, Slijkerman P, van Raalte DH, Handoko ML, de Groot NMS, Grewal N, Klautz RJM, Eringa EC, Brundel BJJM. Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY). Cardiovasc Drugs Ther 2025:10.1007/s10557-025-07693-2. [PMID: 40227474 DOI: 10.1007/s10557-025-07693-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/22/2025] [Indexed: 04/15/2025]
Abstract
PURPOSE Interestingly, 30-50% of patients undergoing elective cardiothoracic surgery develop postoperative AF (PoAF). Unfortunately, preventive PoAF therapy is still suboptimal. In our previous studies, we showed that oral Geranylgeranylacetone (GGA) administration increased cardioprotective heat shock protein (HSP) protecting against AF onset and progression in clinically relevant animal model studies. METHODS The GENIALITY study is a phase II single-center, double-blind, placebo-controlled randomized trial comparing the efficacy of GGA in preventing PoAF. Participants (N = 146) are adult patients, without any registered history of AF, undergoing elective open-heart surgery for valvular disease, coronary artery bypass grafting, or concomitant, and are allocated with ratio 1:1 in treatment or placebo groups. Daily administration of 300 mg of GGA or placebo starts 5 days before until 3 days after surgery. Cardiac rhythm will be monitored using a Holter monitoring post-surgery until hospital discharge. Additionally, blood samples, right atrial appendage tissue, and epicardial adipose tissue will be collected to assess proteostasis levels. RESULTS The primary endpoint is the assessment of PoAF incidence in the GGA group compared to the placebo group. Secondary endpoints include the evaluation of HSP levels through biochemical analysis in both blood and atrial tissue. CONCLUSION The GENIALITY study aims to reduce PoAF incidence in the GGA group compared to the placebo group. Herewith, we expect to obtain proof of concept for a beneficial effect of GGA in preventing PoAF in patients undergoing cardiothoracic surgery. TRIAL REGISTRATION: Clinical Trial Information System (CTIS) registry: 2024-514743-28-00. Authorized on September 30th 2024.
Collapse
Affiliation(s)
- Kennedy S Ramos
- Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands.
| | - Soufiane Nassiri
- Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Leonoor F J Wijdeveld
- Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands
| | - Reinier L van der Palen
- Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands
| | | | | | - Pieter Slijkerman
- Innovation Exchange Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Daniel H van Raalte
- Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - M Louis Handoko
- Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | | | - Nimrat Grewal
- Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands
- Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Robert J M Klautz
- Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands
- Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Etto C Eringa
- Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands
- Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
| | - Bianca J J M Brundel
- Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands.
| |
Collapse
|
2
|
van Schie MS, Veen D, Kharbanda RK, Heida A, Starreveld R, van Schaagen FRN, Bogers AJJC, Taverne YJHJ, de Groot NMS. Characterization of pre-existing arrhythmogenic substrate associated with de novo early and late postoperative atrial fibrillation. Int J Cardiol 2022; 363:71-79. [PMID: 35705170 DOI: 10.1016/j.ijcard.2022.06.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 06/01/2022] [Accepted: 06/10/2022] [Indexed: 01/08/2023]
Abstract
BACKGROUND PoAF is the most common complication after cardiac surgery and may occur in patients with pre-existing arrhythmogenic substrate. Characterization of this substrate could aid in identifying patients at risk for PoAF. We therefore compared intra-atrial conduction parameters and electrogram morphology between patients without and with early- (≤5 days after surgery) and late- (up to 5 years) postoperative atrial fibrillation (PoAF). METHODS AND RESULTS Epicardial mapping of the right and left atrium and Bachmann's Bundle (BB) was performed during sinus rhythm (SR) in 263 patients (207male, 67 ± 11 years). Unipolar potentials were classified as single, short or long double and fractionated potentials. Unipolar voltage, fractionation delay (time difference between the first and last deflection), conduction velocity (CV) and conduction block (CB) prevalence were measured. Comparing patients without (N = 166) and with PoAF (N = 97), PoAF was associated with lower CV and more CB at BB. Unipolar voltages were lower and more low-voltage areas were found at the left and right atrium and BB in PoAF patients. These differences were more pronounced in patients with late-PoAF (6%), which could even occur up to 5 years after surgery. Although several electrophysiological parameters were related to PoAF, age was the only independent predictor. CONCLUSIONS Patients with de novo PoAF have more extensive arrhythmogenic substrate prior to cardiac surgery compared to those who remained in SR, which is even more pronounced in late-PoAF patients. Future studies should evaluate whether intra-operative electrophysiological examination enables identification of patients at risk for developing PoAF and hence (preventive) therapy.
Collapse
Affiliation(s)
- Mathijs S van Schie
- Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Danny Veen
- Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Rohit K Kharbanda
- Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Annejet Heida
- Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Roeliene Starreveld
- Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Frank R N van Schaagen
- Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Ad J J C Bogers
- Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Yannick J H J Taverne
- Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands
| | | |
Collapse
|
3
|
Harken AH. Commentary: New sight, lost sight, insight, and novel sight. JTCVS OPEN 2021; 6:130. [PMID: 36003584 PMCID: PMC9390517 DOI: 10.1016/j.xjon.2021.01.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 01/25/2021] [Accepted: 01/26/2021] [Indexed: 12/02/2022]
Affiliation(s)
- Alden H Harken
- University of California, San Francisco, East Bay, Oakland, Calif (retired)
| |
Collapse
|